Clarin reports Lilly plans to file with the FDA in early 2027, and doctors warn about gray-market 'RETA' vials sold as research products.
Recap by typeshit. Full story at Clarin.com.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
Her point: food industry habits and sedentary lifestyles that drove weight gain are still there, even as millions start these medications.
Fallon says semaglutide and tirzepatide pull in about 60% of the combined run rate revenue of Anthropic and OpenAI, at a sixth of the reach.
Loading…